Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $6.8000 (17.65%) ($5.9000 - $6.9200) on Mon. Oct. 28, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.01% (three month average) | RSI | 93 | Latest Price | $6.8000(17.65%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 4.4% a day on average for past five trading days. | Weekly Trend | TGTX advances 7.1% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(58%) IBB(57%) ARKK(56%) IWO(56%) | Factors Impacting TGTX price | TGTX will decline at least -2.005% in a week (0% probabilities). VIXM(-39%) VXX(-38%) TLT(-8%) UUP(-7%) IGOV(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.005% (StdDev 4.01%) | Hourly BBV | 0 () | Intraday Trend | 15.3% | | | |
|
5 Day Moving Average | $5.9(15.25%) | 10 Day Moving Average | $5.7(19.3%) | 20 Day Moving Average | $5.46(24.54%) | To recent high | -10.9% | To recent low | 33.3% | Market Cap | $861m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |